International Stem Cell (OTCMKTS:ISCO) Releases Quarterly Earnings Results

International Stem Cell (OTCMKTS:ISCO) released its quarterly earnings data on Monday. The biotechnology company reported ($0.04) earnings per share for the quarter, Zacks reports. The firm had revenue of $2.15 million for the quarter.

International Stem Cell Stock Performance

International Stem Cell stock remained flat at $0.17 during midday trading on Wednesday. The company had a trading volume of 10,089 shares, compared to its average volume of 5,407. International Stem Cell has a fifty-two week low of $0.11 and a fifty-two week high of $0.27. The company has a market cap of $1.36 million, a price-to-earnings ratio of -2.83 and a beta of 0.13. The firm has a 50 day moving average price of $0.15 and a 200-day moving average price of $0.15.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.